The HERCULES study of tolebrutinib is the first and only to show reduced confirmed disability progression at 6 months in nonrelapsing secondary progressive multiple sclerosis (MS). The HERCULES ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...

Resistance training is effective for improving gait speed in individuals with multiple sclerosis. The intensity and duration of resistance training are important factors in determining the magnitude ...

"After considering the association between higher number of pregnancies and delay in progressive MS, together with each patient’s current disease phase and activity, MS itself may not represent a main ...

Three investigators and their teams have received funding for clinical trial development projects as part of the International Progressive MS Alliance’s Experimental Medicine Trial Awards. These ...

The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients. Ibudilast intervention in patients with progressive multiple ...

Secondary progressive multiple sclerosis (SPMS) usually develops after years of relapsing-remitting multiple sclerosis (RRMS) and leads to steadily worsening symptoms and disability over time. SPMS ...

The International Progressive MS Alliance announces the launch of its MS Clinical and Imaging Data Resource (CIDR), which provides the academic and research community access to anonymized and ...

The number of cortical lesions at baseline may indicate a patient's risk of developing secondary progressive multiple sclerosis (MS), according to new research. Cortical lesions also may be an early ...